Adaptin Bio, Inc. 2025 Annual Report: Key Insights for Investors

Executive Summary

Adaptin Bio, Inc. (“Adaptin” or the “Company”) has published its annual report for the fiscal year ended December 31, 2025. This comprehensive update provides critical information for current and prospective shareholders, including business progress, financial performance, risk factors, and strategic outlook. The report contains details that could significantly impact the valuation of the Company and its common stock, especially given its status as a pre-commercial, emerging growth company in the life sciences sector.

Business Overview and Milestones

• Core Technology: Adaptin is developing and commercializing products based on proprietary technology that enhances drug delivery to the brain and other tissues. This technology was licensed from Duke University in 2023 and is aimed at addressing various indications with unmet medical needs.
• Corporate Structure: Adaptin underwent a business combination (merger) on February 11, 2025, resulting in its current corporate structure and name change from Unite Acquisition 1 Corp.
• Location: Headquarters in Charlotte, NC, operating under a month-to-month lease. The company believes its current facilities are adequate and expects to obtain additional space as needed.
• Website and Contact: Investors can access reports and updates through www.adaptinbio.com.

Financial Highlights

• Public Float: As of June 30, 2025, Adaptin’s public float was approximately \$9.3 million.
• Shares Outstanding: As of March 26, 2026, the Company reported 8,786,229 shares of common stock outstanding held by 152 shareholders.
• Operating Results:
  • Research and development expenses decreased by 3% year-over-year, totaling \$1.77 million for 2025 versus \$1.82 million in 2024.
  • General and administrative expenses increased, reflecting costs associated with becoming a public company, executive compensation, stock-based compensation, and professional services.
  • Interest expense decreased by 79%, primarily due to the conversion of all outstanding debt during the merger and capital raise in February 2025.
  • Net cash used in operating activities increased sharply to \$(4.78) million in 2025 from \$(0.65) million in 2024, reflecting higher spending on R&D and public company overhead.
  • Net cash provided by financing activities was \$5.2 million in 2025, up from \$0.68 million in 2024, mainly due to capital raised in connection with the merger and offering.
• Bridge Financings:
  The Company raised \$1.5 million in bridge financings in 2023-2024 through secured promissory notes and convertible notes, with accompanying warrants. All debt was converted during the merger.
• Cash Position:
  Net increase in cash during 2025 was \$425,089, compared to only \$29,331 in 2024—a 1349% increase.
• Dividend Policy:
  Adaptin has not paid any cash dividends to date. Future dividends depend on financial performance and Board discretion.

Shareholder & Price-Sensitive Considerations

• Stock Market Status:
  Adaptin’s common stock is not listed or traded on any national securities exchange or over-the-counter market. There is currently no active trading market for its shares. This is a major factor for investors, as liquidity is limited and share valuation is subject to private placements and investor sentiment.
• Emerging Growth Company Status:
  Adaptin qualifies as an emerging growth company under the JOBS Act, allowing it to take advantage of reduced reporting and disclosure requirements, such as:
  • No requirement for auditor attestation of internal controls under Section 404 of Sarbanes-Oxley.
  • Reduced executive compensation disclosures.
  • Exemption from non-binding advisory votes on executive compensation and golden parachute payments.
  • Delayed adoption of new accounting standards compared to other public companies.

  These exemptions may affect transparency and comparability for investors.

• Risks & Uncertainties:
  • Highly competitive and rapidly changing industry.
  • Uncertainties regarding clinical development, regulatory approval, and commercialization timelines.
  • Potential impacts from macroeconomic trends, tariffs, inflation, and interest rates, which remain high and volatile.
  • No material cybersecurity incidents to date, but ongoing risks are acknowledged.
  • The company is not required to disclose risk factors in detail as a “smaller reporting company.”
• Legal Proceedings:
  Adaptin is not aware of any pending or threatened legal proceedings, which is positive for risk assessment.
• Recent Sales of Unregistered Securities:
  The company completed several private placements and offerings in 2025, details of which are disclosed in Form 8-K and Form 10-Q filings.

Forward-Looking Statements & Strategic Outlook

Adaptin’s management has outlined forward-looking statements regarding its ability to raise additional capital, develop and commercialize product candidates, secure FDA approvals, achieve market acceptance, and navigate industry and macroeconomic challenges. These statements are subject to significant uncertainties and risks, and actual results may differ materially from projections. The company’s future depends on successful execution of its R&D, regulatory, and commercialization strategies.

Conclusion: Potential Share Price Impacts

• The lack of a trading market and the ongoing capital requirements means the share price may be highly sensitive to news of successful fundraising, clinical milestones, regulatory progress, or strategic partnerships.
• Any announcement of FDA approval, commercialization, or listing on an exchange would be significant and could substantially affect share value.
• The company’s current cash position, increased financing, and conversion of debt are positive, but ongoing operational losses and R&D costs highlight the need for future capital and successful pipeline development.
• Emerging growth company and smaller reporting company status may impact investor perception regarding transparency and governance.

Disclaimer

This article is based on Adaptin Bio, Inc.’s 2025 Annual Report and is intended for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View ADAPTIN BIO, INC. Historical chart here